Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.68 |
| ▸ | RAB9A | P51151 | 10/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.68 |
| ▸ | HPGD | P15428 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.63 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | GFER | P55789 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376001 | 0.88 | ALDH1A1 (0.64) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2270976 | 0.87 | NPC1 (0.78) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2268609 | 0.87 | NPC1 (0.78) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29363950 | 0.87 | NPC1 (0.78) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29364223 | 0.87 | NPC1 (0.78) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL20943719 | 0.86 | NPC1 (0.72) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL12209706 | 0.86 | NPC1 (0.72) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL12076741 | 0.86 | ALDH1A1 (0.62) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL12209714 | 0.85 | NPC1 (0.70) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5834881 | 0.84 | NPC1 (0.70) | NPC1KDM4ERAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | claimed |
| CN-115583922-B | Fluorine-containing N- (3- (benzoxazol-2-yl) phenyl) amide compound and preparation method and application thereof | 黄山学院 | 2023-09-19 | — | — | CN | claimed |
| CN-115583922-A | Fluorine-containing N- (3- (benzoxazole-2-yl) phenyl) amide compound and preparation method and application thereof | 黄山学院 | 2023-01-10 | — | — | CN | claimed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | claimed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| EP-1919875-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | Astex Therapeutics Limited (GB) | 2008-05-14 | — | — | EP | claimed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| WO-2025125248-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS THAT OVEREXPRESS TSPAN1 | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2025-06-19 | — | — | WO | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| CN-115583922-B | Fluorine-containing N- (3- (benzoxazol-2-yl) phenyl) amide compound and preparation method and application thereof | 黄山学院 | 2023-09-19 | — | — | CN | disclosed |
| CN-115583922-B | Fluorine-containing N- (3- (benzoxazol-2-yl) phenyl) amide compound and preparation method and application thereof | 黄山学院 | 2023-09-19 | — | — | CN | disclosed |
| WO-2004067480-A2 | SUBSTITUTED PHENYLUREA DERIVATIVES AS HDAC INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067480-A2 | SUBSTITUTED PHENYLUREA DERIVATIVES AS HDAC INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
| US-6211220-B1 | ANTITUMOR AGENTS AND ANTICARCIINOGENIC AGENTS | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1994029277-A1 | AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-22 | — | — | WO | disclosed |
| US-4167394-A | MONOAZO DYES HAVING INDOLE OR PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | NPC1 268/4885KDM4E 1291/4885RAB9A 1353/4885 |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | ATG7, GOT1, ULK1 | NPC1 254/4885KDM4E 402/4885RAB9A 1464/4885 |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | NPC1 457/4885KDM4E 3386/4885RAB9A 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.